Search for other papers by Atsuya Tsuru in
Google Scholar
PubMed
Search for other papers by Mikihiro Yoshie in
Google Scholar
PubMed
Search for other papers by Mei Suzuki in
Google Scholar
PubMed
Search for other papers by Hiroki Mochizuki in
Google Scholar
PubMed
Search for other papers by Satoshi Kametaka in
Google Scholar
PubMed
Search for other papers by Takako Ohmaru-Nakanishi in
Google Scholar
PubMed
Search for other papers by Mana Azumi in
Google Scholar
PubMed
Search for other papers by Kazuya Kusama in
Google Scholar
PubMed
Search for other papers by Kiyoko Kato in
Google Scholar
PubMed
Search for other papers by Kazuhiro Tamura in
Google Scholar
PubMed
Mononuclear cytotrophoblasts (CTs) differentiate and fuse to form multinuclear syncytiotrophoblasts (STs), which produce human chorionic gonadotropin (hCG) and progesterone to maintain pregnancy. Impaired differentiation and fusion of CTs to form STs are associated with hypertensive disorders of pregnancy and fetal growth restriction. Progesterone receptor membrane component 1 (PGRMC1) is a multifunctional single transmembrane heme-binding protein. We previously demonstrated that downregulation of PGRMC1 promotes endometrial stromal cell differentiation (decidualization). Here, we explored the role of PGRMC1 in trophoblast differentiation and fusion. PGRMC1 expression was lower in STs than in CTs of first-trimester placental tissues. PGRMC1 expression in BeWo cells (a trophoblast-derived choriocarcinoma cell line) decreased upon dibutyryl-cAMP (db-cAMP)-induced differentiation. Both inhibition and knockdown of PGRMC1 stimulated hCG production in the presence of db-cAMP. Furthermore, a quantitative cell fusion assay we developed revealed that inhibition and knockdown of PGRMC1 enhanced db-cAMP-stimulated cell fusion. Peroxisome proliferator-activated receptor γ (PPARγ) agonists decreased PGRMC1 expression and stimulated the cell fusion in BeWo cells. These findings suggest that downregulation of PGRMC1 expression in part through activation of PPARγ during trophoblast differentiation promotes hCG production and cell fusion for formation and maintenance of placental villi during pregnancy.
Medicines & Healthcare products Regulatory Agency, Research and Innovation group, Hertfordshire, UK
Search for other papers by Matthew T F Lamaudière in
Google Scholar
PubMed
Search for other papers by Mark C Turner in
Google Scholar
PubMed
Institute of Precision & Diagnostic Medicine, University Hospitals of Coventry and Warwickshire, NHS trust, Coventry, UK
Search for other papers by Ramesh P Arasaradnam in
Google Scholar
PubMed
Search for other papers by Igor Y Morozov in
Google Scholar
PubMed
Over the last two decades, it has become clear that the human gut microbiota, a complex community of bacteria, archaea, fungi and viruses, are a critical determinant of human health and disease. Microbiota-derived metabolites provide the host with energy, protect against pathogens, modulate immune and endocrine systems as well as the level of reactive oxygen species in the gut. It has come with no surprise that the human gut microbiota is also linked to the production, utilisation and regulation of host hormones. This implies that the gut microbiota is capable of influencing human behaviour, appetite regulation and metabolism as well as development and immunity. Many of the advances in the field of crosstalk between the gut microbiota and host health, disease and behaviours are generally based on DNA analyses of microbial populations and transplantation of monocultured commensal species to germ-free animals. Recent reports on the activity of the gut microbiota in gastrointestinal diseases such as inflammatory bowel disease and colorectal cancer have highlighted two important points. First, microbial DNA-based abundance does not always correlate with their level of activity and secondly, that metabolism of the complex gut microbiota is regulated by host health status, including the production and metabolism of several human hormones. In this review, we will discuss the lessons learnt from studying the activity and metabolism of the human gut microbiota in health and across gastrointestinal diseases, and how these findings can shape future research on the microbiome–gut–endocrine axis.
Search for other papers by Kristen R Lednovich in
Google Scholar
PubMed
Search for other papers by Sophie Gough in
Google Scholar
PubMed
Search for other papers by Medha Priyadarshini in
Google Scholar
PubMed
Search for other papers by Nupur Pandya in
Google Scholar
PubMed
Search for other papers by Chioma Nnyamah in
Google Scholar
PubMed
Search for other papers by Kai Xu in
Google Scholar
PubMed
Search for other papers by Barton Wicksteed in
Google Scholar
PubMed
Search for other papers by Sidharth Mishra in
Google Scholar
PubMed
Search for other papers by Shalini Jain in
Google Scholar
PubMed
Jesse Brown Veterans Affairs Medical Center, Chicago, Illinois, USA
Search for other papers by Joseph L Zapater in
Google Scholar
PubMed
Search for other papers by Jose Cordoba-Chacon in
Google Scholar
PubMed
Search for other papers by Hariom Yadav in
Google Scholar
PubMed
Jesse Brown Veterans Affairs Medical Center, Chicago, Illinois, USA
Search for other papers by Brian T Layden in
Google Scholar
PubMed
Short-chain fatty acids (SCFAs) are key nutrients that play a diverse set of roles in physiological function, including regulating metabolic homeostasis. Generated through the fermentation of dietary fibers in the distal colon by the gut microbiome, SCFAs and their effects are partially mediated by their cognate receptors, including free fatty acid receptor 2 (FFA2). FFA2 is highly expressed in the intestinal epithelial cells, where its putative functions are controversial, with numerous in vivo studies relying on global knockout mouse models to characterize intestine-specific roles of the receptor. Here, we used the Villin-Cre mouse line to generate a novel, intestine-specific knockout mouse model for FFA2 (Vil-FFA2) to investigate receptor function within the intestine. Because dietary changes are known to affect the composition of the gut microbiome, and can thereby alter SCFA production, we performed an obesogenic challenge on male Vil-FFA2 mice and their littermate controls (FFA2-floxed, FFA2fl/fl) to identify physiological changes on a high-fat, high-sugar ‘Western diet’ (WD) compared to a low-fat control diet (CD). We found that the WD-fed Vil-FFA2 mice were transiently protected from the obesogenic effects of the WD and had lower fat mass and improved glucose homeostasis compared to the WD-fed FFA2fl/fl control group during the first half of the study. Additionally, major differences in respiratory exchange ratio and energy expenditure were observed in the WD-fed Vil-FFA2 mice, and food intake was found to be significantly reduced at multiple points in the study. Taken together, this study uncovers a novel role of intestinal FFA2 in mediating the development of obesity.
Search for other papers by Thomas G Hill in
Google Scholar
PubMed
Search for other papers by Lorna I F Smith in
Google Scholar
PubMed
Search for other papers by Inmaculada Ruz-Maldonado in
Google Scholar
PubMed
Search for other papers by Peter M Jones in
Google Scholar
PubMed
Search for other papers by James E Bowe in
Google Scholar
PubMed
During pregnancy the maternal pancreatic islets of Langerhans undergo adaptive changes to compensate for gestational insulin resistance. The lactogenic hormones are well established to play a key role in regulating the islet adaptation to pregnancy, and one of the mechanisms through which they act is through upregulating β-cell serotonin production. During pregnancy islet serotonin levels are significantly elevated, where it is released from the β-cells to drive the adaptive response through paracrine and autocrine effects. We have previously shown that placental kisspeptin (KP) also plays a role in promoting the elevated insulin secretion and β-cell proliferation observed during pregnancy, although the precise mechanisms involved are unclear. In the present study we investigated the effects of KP on expression of pro-proliferative genes and serotonin biosynthesis within rodent islets. Whilst KP had limited effect on pro-proliferative gene expression at the time points tested, KP did significantly stimulate expression of the serotonin biosynthesis enzyme Tph-1. Furthermore, the islets of pregnant β-cell-specific GPR54 knockdown mice were found to contain significantly fewer serotonin-positive β-cells when compared to pregnant controls. Our previous studies suggested that reduced placental kisspeptin production, with consequent impaired kisspeptin-dependent β-cell compensation, may be a factor in the development of GDM in humans. These current data suggest that, similar to the lactogenic hormones, KP may also contribute to serotonin biosynthesis and subsequent islet signalling during pregnancy. Furthermore, upregulation of serotonin biosynthesis may represent a common mechanism through which multiple signals might influence the islet adaptation to pregnancy.
Neuroscience Research Center, Hebei Medical University, Shijiazhuang, Hebei, China
Hebei Key Laboratory of Neurodegenerative Disease Mechanism, Hebei Medical University, Shijiazhuang, Hebei, China
Search for other papers by Yizhou Zhang in
Google Scholar
PubMed
Search for other papers by Meiqin Chen in
Google Scholar
PubMed
Neuroscience Research Center, Hebei Medical University, Shijiazhuang, Hebei, China
Hebei Key Laboratory of Neurodegenerative Disease Mechanism, Hebei Medical University, Shijiazhuang, Hebei, China
Search for other papers by Huan Chen in
Google Scholar
PubMed
Search for other papers by Shixiong Mi in
Google Scholar
PubMed
Neuroscience Research Center, Hebei Medical University, Shijiazhuang, Hebei, China
Hebei Key Laboratory of Neurodegenerative Disease Mechanism, Hebei Medical University, Shijiazhuang, Hebei, China
Search for other papers by Chang Wang in
Google Scholar
PubMed
Search for other papers by Hongchun Zuo in
Google Scholar
PubMed
Search for other papers by Leigang Song in
Google Scholar
PubMed
Neuroscience Research Center, Hebei Medical University, Shijiazhuang, Hebei, China
Hebei Key Laboratory of Neurodegenerative Disease Mechanism, Hebei Medical University, Shijiazhuang, Hebei, China
Search for other papers by Juan Du in
Google Scholar
PubMed
Neuroscience Research Center, Hebei Medical University, Shijiazhuang, Hebei, China
Hebei Key Laboratory of Neurodegenerative Disease Mechanism, Hebei Medical University, Shijiazhuang, Hebei, China
Search for other papers by Huixian Cui in
Google Scholar
PubMed
Neuroscience Research Center, Hebei Medical University, Shijiazhuang, Hebei, China
Hebei Key Laboratory of Neurodegenerative Disease Mechanism, Hebei Medical University, Shijiazhuang, Hebei, China
Search for other papers by Sha Li in
Google Scholar
PubMed
Aging-related reduction in androgen levels may be a possible risk factor for neurodegenerative diseases and contribute to cognitive impairment. Androgens may affect synaptic function and cognition in an androgen receptor (AR)-independent manner; however, the mechanisms connecting theses effects are unknown. Therefore, we used testicular feminization mutation (Tfm) male mice, a model with AR mutation, to test the effects of testosterone on synaptic function and cognition. Our results showed that testosterone ameliorated spatial memory deficit and neuronal damage, and increased dendritic spines density and postsynaptic density protein 95 (PSD95) and glutamate receptor 1 (GluA1) expression in the hippocampus of Tfm male mice. And these effects of testosterone were not inhibited by anastrozole, which suppressed conversion of testosterone to estradiol. Mechanistically, testosterone activated the extracellular signal-related kinase 1/2 (Erk1/2) and cyclic adenosine monophosphate response element-binding protein (CREB) in the hippocampus of Tfm male mice. Meanwhile, Erk1/2 inhibitor SCH772984 blocked the upregulation of phospho-CREB, PSD95, and GluA1 induced by testosterone in HT22 cells pretreated with flutamide, an androgen antagonist. Collectively, our data indicate that testosterone may ameliorate hippocampal synaptic damage and spatial memory deficit by activating the Erk1/2–CREB signaling pathway in an AR-independent manner.
Search for other papers by Julia K Panzer in
Google Scholar
PubMed
Search for other papers by Alejandro Caicedo in
Google Scholar
PubMed
Long lagging behind insulin, glucagon research has caught up in large part, thanks to technological breakthroughs. Here we review how the field was propelled by the development of novel techniques and approaches. The glucagon radioimmunoassay and islet isolation are methods that now seem trivial, but for decades they were crucial in defining the biology of the pancreatic alpha cell and the role of glucagon in glucose homeostasis. More recently, mouse models have become the main workhorse of this research effort, if not of biomedical research in general. The mouse model allowed detailed mechanistic studies that are revealing alpha cell functions beyond its canonical glucoregulatory role. A recent profusion of gene expression and transcription regulation studies is providing new vistas into what constitutes alpha cell identity. In particular, the combination of transcriptomic techniques with functional recordings promises to move molecular guesswork into real-time physiology. The challenge right now is not to get enamored with these powerful techniques and to make sure that the research continues to be transformative and paradigm shifting. We should imagine a future in which the biology of the alpha cell will be studied at single-cell resolution, non-invasively, and in real time in the human body.
Search for other papers by Colin Farquharson in
Google Scholar
PubMed
Search for other papers by Ruth Andrew in
Google Scholar
PubMed
Department of Child Health, University of Arizona College of Medicine, Phoenix, Arizona, USA
Search for other papers by J Bryce Ortiz in
Google Scholar
PubMed
Search for other papers by Sebastian Tellez in
Google Scholar
PubMed
Department of Biology and Biochemistry, University of Bath, Bath, United Kingdom
Search for other papers by Giri Rampal in
Google Scholar
PubMed
Search for other papers by Grant S Mannino in
Google Scholar
PubMed
Search for other papers by Nicole Couillard in
Google Scholar
PubMed
Search for other papers by Matias Mendez in
Google Scholar
PubMed
Search for other papers by Tabitha R F Green in
Google Scholar
PubMed
Search for other papers by Sean M Murphy in
Google Scholar
PubMed
Search for other papers by Rachel K Rowe in
Google Scholar
PubMed
Traumatic brain injury (TBI) can damage the hypothalamus and cause improper activation of the growth hormone (GH) axis, leading to growth hormone deficiency (GHD). GHD is one of the most prevalent endocrinopathies following TBI in adults; however, the extent to which GHD affects juveniles remains understudied. We used postnatal day 17 rats (n = 83), which model the late infantile/toddler period, and assessed body weights, GH levels, and number of hypothalamic somatostatin neurons at acute (1, 7 days post injury (DPI)) and chronic (18, 25, 43 DPI) time points. We hypothesized that diffuse TBI would alter circulating GH levels because of damage to the hypothalamus, specifically somatostatin neurons. Data were analyzed with generalized linear and mixed effects models with fixed effects interactions between the injury and time. Despite similar growth rates over time with age, TBI rats weighed less than shams at 18 DPI (postnatal day 35; P = 0.03, standardized effect size [d] = 1.24), which is around the onset of puberty. Compared to shams, GH levels were lower in the TBI group during the acute period (P = 0.196; d = 12.3) but higher in the TBI group during the chronic period (P = 0.10; d = 52.1). Although not statistically significant, TBI-induced differences in GH had large standardized effect sizes, indicating biological significance. The mean number of hypothalamic somatostatin neurons (an inhibitor of GH) positively predicted GH levels in the hypothalamus but did not predict GH levels in the somatosensory cortex. Understanding TBI-induced alterations in the GH axis may identify therapeutic targets to improve the quality of life of pediatric survivors of TBI.
Centro de Microscopia Electrónica, Facultad de Ciencias Médicas, Universidad Nacional de Córdoba, Córdoba, Argentina
Search for other papers by Jonathan Toledo in
Google Scholar
PubMed
Centro de Microscopia Electrónica, Facultad de Ciencias Médicas, Universidad Nacional de Córdoba, Córdoba, Argentina
Search for other papers by Pablo Aníbal Perez in
Google Scholar
PubMed
Search for other papers by Mical Zanetti in
Google Scholar
PubMed
Search for other papers by Graciela Díaz-Torga in
Google Scholar
PubMed
Centro de Microscopia Electrónica, Facultad de Ciencias Médicas, Universidad Nacional de Córdoba, Córdoba, Argentina
Search for other papers by Jorge Humberto Mukdsi in
Google Scholar
PubMed
Centro de Microscopia Electrónica, Facultad de Ciencias Médicas, Universidad Nacional de Córdoba, Córdoba, Argentina
Search for other papers by Silvina Gutierrez in
Google Scholar
PubMed
Due to the current limited knowledge about the role of filamin A (FLNA) in pituitary tumour progression, we aimed to analyse FLNA expression levels and its impact on aggressive markers of pituitary neuroendocrine tumours (PitNETs), using an integrative approach of in vivo and in vitro models and human samples. An increase in the expression levels of FLNA was observed in the advanced tumoural stages of the hyperplastic adenomatous pituitary model, concomitant with a decrease in cell proliferation and with a modification in the subcellular localisation of this protein. Similarly, overexpression of FLNA in the somatolactotropic GH3 cell line induced a decrease in the cell proliferation, promoted a migratory phenotype, increased invasion activity, and decreased the prolactin secretion. Cyclin D1 (CCND1) and cyclin-dependent kinase 4 (CDK4) expression increased in both models in correlation with the increase observed in FLNA levels. When human tissues were analysed a significant increase of FLNA was observed in PitNETs compared to normal pituitary gland, with heterogeneous intracellular localisation. Higher levels of FLNA expression were observed in tumours with invasive characteristics. These results underline the crucial roles of FLNA as a modulator of pathological markers and as a potential prognostic marker in pituitary tumours.
